In TP53 mutant cells, USP7 exhibited anti-proliferative effects by activating the apoptotic and E2F pathways, distinguishing it from inhibitors with no impact on cell growth.476 These findings highlight the potential of USP7 degraders as a therapeutic approach for modulating the intricate interplay between USP7 and p53 in cancer treatment. The gene discussed is TP53; the disease is cancer.